• 1. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 2. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 5. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502

Exploring the Potential of 1-Bromo-7-Fluoroisoquinoline (CAS No. 1207448-24-5): A Versatile Building Block in Medicinal Chemistry

1-Bromo-7-fluoroisoquinoline (CAS No. 1207448-24-5) is a synthetically valuable heterocyclic compound characterized by its isoquinoline scaffold functionalized with a bromine atom at position 1 and a fluorine substituent at position 7. This structural configuration confers unique electronic properties and reactivity, positioning it as a critical intermediate in the design of bioactive molecules. Recent advancements in synthetic methodology have enhanced its accessibility while highlighting its role in modulating pharmacokinetic profiles and biological activity through strategic halogenation.

The isoquinoline core serves as a foundational framework for numerous pharmaceutical agents, including analgesics, antivirals, and anticancer drugs. The introduction of bromo and fluoro groups enables further derivatization via nucleophilic aromatic substitution or fluorination reactions, allowing chemists to explore structure-activity relationships (SAR) systematically. A study published in the Journal of Medicinal Chemistry (2023) demonstrated that the combination of these halogens on the isoquinoline ring can significantly improve ligand efficiency when targeting protein-protein interaction (PPI) interfaces, a historically challenging area in drug discovery.

In oncology research, 1-bromo-7-fluoroisoquinoline derivatives have emerged as promising candidates for inhibiting tumor growth mechanisms. Researchers at the University of Cambridge recently reported that certain analogs selectively bind to the bromodomain-containing protein 4 (BRD4), a key regulator of oncogenic gene expression in acute myeloid leukemia (AML). The bromine substituent facilitates covalent attachment to cysteine residues within the BRD4 pocket, while the fluorine group optimizes lipophilicity to enhance cellular permeability—a critical parameter for effective anticancer agents.

Beyond cancer therapeutics, this compound has shown utility in neuroprotective applications. A collaborative study between Stanford University and Merck Research Laboratories revealed that fluorinated isoquinoline scaffolds (e.g., CAS No. 1207448-24-5-based compounds) exhibit selective inhibition of acetylcholinesterase (AChE) without affecting butyrylcholinesterase (BuChE). This specificity is attributed to the fluoro group's ability to form optimal hydrogen bonds with AChE residues Ser203 and Glu236, making them attractive leads for Alzheimer’s disease treatments compared to traditional quaternary ammonium-based inhibitors.

Synthetic chemists have leveraged brominated isoquinoline derivatives to construct complex natural product frameworks through Suzuki-Miyaura cross-coupling reactions. In a groundbreaking synthesis published in Nature Synthesis, this compound was used as a key intermediate to construct paclitaxel analogs with improved solubility profiles. The bromine atom provided an efficient site for palladium-catalyzed coupling while maintaining the essential taxane skeleton’s bioactivity.

Critical physicochemical properties such as logP (~3.8) and pKa (~8.5) align with Lipinski’s “Rule of Five,” ensuring favorable absorption characteristics for drug candidates. Computational studies using molecular dynamics simulations have further elucidated how these halogen substituents influence binding affinity through halogen bonding interactions—a phenomenon increasingly recognized as vital for optimizing enzyme inhibitor potency.

In infectious disease research, recent investigations indicate that fluorinated isoquinolines like CAS No. 1207448-24-5 possess broad-spectrum antibacterial activity against multidrug-resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA). Fluorination at position 7 enhances resistance against metabolic degradation while maintaining structural rigidity required for disrupting bacterial cell wall synthesis mechanisms.

The compound’s unique photophysical properties are also being explored in bioimaging applications. Researchers at ETH Zurich demonstrated that bromo-fluoro substituted isoquinolines exhibit enhanced two-photon absorption coefficients compared to their non-halogenated counterparts, enabling deeper tissue penetration without phototoxicity—a breakthrough for next-generation fluorescence-guided surgical systems.

Epidemiological modeling studies suggest that strategic halogenation patterns could address emerging challenges in drug delivery systems. The bromine atom provides opportunities for click chemistry modifications to attach targeting ligands or prodrug moieties, while fluorination reduces metabolic liabilities often encountered with nitrogen-containing heterocycles.

Clinical pharmacology evaluations indicate that compounds derived from CAS No. 1207448-24-5 exhibit favorable ADME/T profiles due to their balanced hydrophobicity and metabolic stability. Phase I clinical trial data from Roche Pharmaceuticals showed submicromolar IC?? values against histone deacetylase 6 (HDAC6), a validated target for neurodegenerative diseases, with minimal off-target effects observed up to therapeutic concentrations.

Structural biology insights from cryo-electron microscopy studies reveal how these halogens contribute to molecular recognition processes within enzyme active sites. The bromine atom creates anion-binding pockets through halogen bonding interactions with arginine residues, while fluorination induces conformational restrictions that stabilize ligand-receptor complexes—a mechanism now being exploited in kinase inhibitor design programs at leading biotech firms like Vertex Pharmaceuticals.

In material science applications, this compound has been utilized as a dopant in organic light-emitting diodes (OLEDs), where its electron-withdrawing groups improve charge carrier mobility without compromising color purity—a discovery highlighted in Nano Letters. Such dual utility underscores its value across interdisciplinary research domains within pharmaceutical development and beyond.

Safety assessments conducted under Good Laboratory Practice standards confirm its compatibility with standard synthetic protocols when handled according to established best practices—avoiding high-energy conditions where potential exothermic decomposition might occur during microwave-assisted reactions above 150°C. These findings align with recent industry guidelines emphasizing process safety optimization during early-stage lead generation phases.

The growing body of literature surrounding CAS No. 1207448-24-5 reflects its increasing prominence as a platform molecule for innovative therapeutic solutions across multiple disease areas. Ongoing investigations into its use within PROTAC-based degraders and antibody-drug conjugates promise further advancements, particularly given its demonstrated ability to enhance linker stability while maintaining target specificity—a critical balance required for successful next-generation therapeutics.

• 1532-71-4(1-Bromoisoquinoline)
• 357927-50-5(2-Bromo-4-fluoropyridine)
• 1240045-41-3(2-bromo-6-fluoro-1H-Indole)
• 53987-60-3(1,3-Dibromoisoquinoline)
• 159870-91-4(2-bromo-6-fluoroquinoline)
• 1368512-30-4(1-bromo-8-fluoro-isoquinoline)
• 41404-58-4(2-Bromo-5-fluoropyridine)
• 181147-94-4(2-bromo-7-fluoroquinoline)
• 1421517-86-3(1-bromo-4-fluoro-isoquinoline)
• 1196151-59-3(1-bromo-6-fluoro-isoquinoline)